ASCO 2024 | Sequencing and treatment strategies in advanced urothelial carcinoma
Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the FDA-approved therapies available for patients who progress on avelumab, such as enfortumab vedotin and sacituzumab govitecan. Considering the negative findings within the Phase III TROPiCS-04 trial (NCT04527991) of sacituzumab govitecan, the importance of effectively sequencing therapies for patients is highlighted. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Rainier Therapeutics
Honoraria – UpToDate
Consulting or Advisory Role – Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding – Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property – UpToDate Bladder Cancer
Travel, Accommodations, Expenses – Ipsen; MSD Oncology; Pfizer
